 Jason Farrar
Concepts (208)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 15 | 2024 | 180 | 3.240 |
Why?
| | Anemia, Diamond-Blackfan | 13 | 2024 | 13 | 2.800 |
Why?
| | Mutation | 15 | 2023 | 1292 | 1.760 |
Why?
| | Ribosomal Proteins | 9 | 2021 | 25 | 1.530 |
Why?
| | Midazolam | 1 | 2024 | 37 | 0.940 |
Why?
| | Hypnotics and Sedatives | 1 | 2024 | 74 | 0.900 |
Why?
| | Neurosurgical Procedures | 1 | 2024 | 123 | 0.860 |
Why?
| | Gene Expression Profiling | 6 | 2023 | 1029 | 0.820 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.770 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2021 | 12 | 0.770 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 214 | 0.670 |
Why?
| | RNA Processing, Post-Transcriptional | 3 | 2014 | 24 | 0.560 |
Why?
| | GATA1 Transcription Factor | 2 | 2017 | 7 | 0.490 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2024 | 59 | 0.480 |
Why?
| | RNA, Ribosomal | 1 | 2014 | 20 | 0.470 |
Why?
| | RNA Precursors | 1 | 2014 | 9 | 0.470 |
Why?
| | Codon, Initiator | 1 | 2014 | 9 | 0.460 |
Why?
| | Point Mutation | 1 | 2014 | 65 | 0.450 |
Why?
| | Humans | 39 | 2024 | 50389 | 0.410 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1189 | 0.400 |
Why?
| | Child, Preschool | 12 | 2021 | 3908 | 0.390 |
Why?
| | Prognosis | 6 | 2024 | 1979 | 0.390 |
Why?
| | Critical Illness | 2 | 2024 | 300 | 0.390 |
Why?
| | Gene Deletion | 1 | 2011 | 267 | 0.350 |
Why?
| | Infant | 9 | 2021 | 3601 | 0.340 |
Why?
| | Child | 16 | 2024 | 6877 | 0.320 |
Why?
| | Female | 14 | 2024 | 26981 | 0.290 |
Why?
| | DNA Methylation | 6 | 2023 | 551 | 0.280 |
Why?
| | Intensive Care Units | 2 | 2024 | 224 | 0.260 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 409 | 0.240 |
Why?
| | Nutritional Support | 1 | 2024 | 35 | 0.240 |
Why?
| | Male | 13 | 2024 | 25718 | 0.240 |
Why?
| | Hemophilia A | 1 | 2024 | 25 | 0.220 |
Why?
| | Gene Rearrangement | 1 | 2024 | 74 | 0.210 |
Why?
| | Prospective Studies | 3 | 2024 | 2414 | 0.210 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 168 | 0.210 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2024 | 326 | 0.210 |
Why?
| | Consensus | 1 | 2024 | 159 | 0.210 |
Why?
| | Osteosarcoma | 1 | 2023 | 45 | 0.210 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 237 | 0.210 |
Why?
| | Azacitidine | 2 | 2023 | 34 | 0.200 |
Why?
| | Chromosome Aberrations | 3 | 2017 | 295 | 0.200 |
Why?
| | Blood Glucose | 1 | 2024 | 443 | 0.200 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 16 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2023 | 179 | 0.190 |
Why?
| | Co-Repressor Proteins | 1 | 2021 | 18 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 74 | 0.180 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 284 | 0.180 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 482 | 0.180 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 107 | 0.180 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2021 | 35 | 0.180 |
Why?
| | B-Lymphocytes | 1 | 2021 | 175 | 0.180 |
Why?
| | Chromatin | 1 | 2021 | 138 | 0.170 |
Why?
| | Leucine | 1 | 2020 | 118 | 0.170 |
Why?
| | Blood Transfusion | 1 | 2020 | 127 | 0.160 |
Why?
| | MicroRNAs | 2 | 2021 | 350 | 0.160 |
Why?
| | Recurrence | 2 | 2022 | 664 | 0.160 |
Why?
| | Ribosomes | 2 | 2009 | 36 | 0.160 |
Why?
| | Adult | 6 | 2024 | 13568 | 0.150 |
Why?
| | Research Report | 1 | 2018 | 16 | 0.150 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 424 | 0.150 |
Why?
| | Adolescent | 6 | 2022 | 6475 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 60 | 0.140 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.140 |
Why?
| | Agammaglobulinemia | 1 | 1996 | 9 | 0.140 |
Why?
| | X Chromosome | 1 | 1996 | 12 | 0.140 |
Why?
| | Genome, Human | 2 | 2021 | 111 | 0.140 |
Why?
| | Phenotype | 3 | 2021 | 736 | 0.130 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.130 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 14 | 0.130 |
Why?
| | Cell Proliferation | 4 | 2021 | 989 | 0.130 |
Why?
| | Aged | 3 | 2024 | 9590 | 0.130 |
Why?
| | Middle Aged | 4 | 2024 | 12460 | 0.130 |
Why?
| | Neutropenia | 1 | 1996 | 114 | 0.130 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 109 | 0.130 |
Why?
| | Registries | 1 | 2018 | 539 | 0.120 |
Why?
| | Young Adult | 5 | 2024 | 4064 | 0.120 |
Why?
| | Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.120 |
Why?
| | Treatment Outcome | 2 | 2023 | 5230 | 0.120 |
Why?
| | K562 Cells | 1 | 2014 | 41 | 0.120 |
Why?
| | Transcription Factors | 3 | 2024 | 566 | 0.120 |
Why?
| | Chromosome Mapping | 3 | 2011 | 158 | 0.110 |
Why?
| | Leukemia, Myeloid | 1 | 2014 | 42 | 0.110 |
Why?
| | Anemia, Macrocytic | 1 | 2013 | 2 | 0.110 |
Why?
| | Cytogenetic Analysis | 1 | 2013 | 80 | 0.110 |
Why?
| | Base Sequence | 3 | 2010 | 657 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 578 | 0.110 |
Why?
| | Infant, Newborn | 3 | 2019 | 2780 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2021 | 1101 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 591 | 0.100 |
Why?
| | Genomics | 1 | 2014 | 284 | 0.100 |
Why?
| | Chromosome Deletion | 2 | 2013 | 140 | 0.100 |
Why?
| | Haploinsufficiency | 1 | 2011 | 14 | 0.100 |
Why?
| | Mosaicism | 1 | 2011 | 18 | 0.100 |
Why?
| | Genotyping Techniques | 1 | 2011 | 20 | 0.100 |
Why?
| | Blotting, Northern | 1 | 2011 | 110 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2008 | 210 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 163 | 0.090 |
Why?
| | Neoplastic Stem Cells | 2 | 2022 | 100 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2017 | 1148 | 0.090 |
Why?
| | Daunorubicin | 2 | 2022 | 12 | 0.090 |
Why?
| | WT1 Proteins | 1 | 2009 | 4 | 0.090 |
Why?
| | Cytarabine | 2 | 2022 | 40 | 0.080 |
Why?
| | Cohort Studies | 2 | 2016 | 1426 | 0.080 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 19 | 0.080 |
Why?
| | Pedigree | 1 | 2008 | 125 | 0.070 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2009 | 142 | 0.070 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2007 | 15 | 0.070 |
Why?
| | Wilms Tumor | 1 | 2007 | 19 | 0.070 |
Why?
| | Genes, Tumor Suppressor | 1 | 2007 | 73 | 0.070 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 579 | 0.070 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2007 | 93 | 0.070 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 799 | 0.070 |
Why?
| | DNA Helicases | 1 | 2008 | 145 | 0.070 |
Why?
| | Mice | 4 | 2023 | 5688 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2021 | 651 | 0.070 |
Why?
| | Models, Biological | 1 | 2009 | 723 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 174 | 0.060 |
Why?
| | Cell Line | 1 | 2008 | 1010 | 0.060 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 73 | 0.060 |
Why?
| | Tacrolimus | 1 | 2005 | 54 | 0.060 |
Why?
| | Insulin, Isophane | 1 | 2024 | 1 | 0.060 |
Why?
| | Transcriptome | 2 | 2017 | 316 | 0.060 |
Why?
| | DNA | 1 | 2008 | 543 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2005 | 80 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2219 | 0.060 |
Why?
| | Nucleosome Assembly Protein 1 | 1 | 2024 | 1 | 0.060 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2024 | 17 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2024 | 82 | 0.060 |
Why?
| | Factor VIII | 1 | 2024 | 23 | 0.060 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.060 |
Why?
| | Proto-Oncogenes | 1 | 2024 | 27 | 0.060 |
Why?
| | DEAD-box RNA Helicases | 1 | 2024 | 32 | 0.060 |
Why?
| | Outpatients | 1 | 2024 | 115 | 0.060 |
Why?
| | Animals | 5 | 2023 | 13173 | 0.060 |
Why?
| | Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.060 |
Why?
| | Nuclear Pore Complex Proteins | 1 | 2023 | 11 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2024 | 33 | 0.050 |
Why?
| | Autoantibodies | 1 | 2024 | 114 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 106 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 174 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2024 | 228 | 0.050 |
Why?
| | Apoptosis | 1 | 2008 | 1094 | 0.050 |
Why?
| | Disease Management | 1 | 2024 | 175 | 0.050 |
Why?
| | Hemorrhage | 1 | 2024 | 197 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2024 | 6223 | 0.050 |
Why?
| | Insulin | 1 | 2024 | 466 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.050 |
Why?
| | Core Binding Factor beta Subunit | 1 | 2021 | 3 | 0.050 |
Why?
| | Myosin Heavy Chains | 1 | 2021 | 21 | 0.050 |
Why?
| | RNA | 1 | 2022 | 169 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2021 | 1419 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2021 | 32 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 58 | 0.050 |
Why?
| | Acetylation | 1 | 2021 | 93 | 0.050 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 120 | 0.050 |
Why?
| | Trans-Activators | 1 | 2021 | 135 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2021 | 115 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 216 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 297 | 0.040 |
Why?
| | Up-Regulation | 1 | 2021 | 449 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2019 | 12 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2021 | 181 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2024 | 763 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2021 | 182 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1399 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 555 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 657 | 0.040 |
Why?
| | Histones | 1 | 2021 | 296 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 386 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 641 | 0.040 |
Why?
| | Pilot Projects | 1 | 2020 | 704 | 0.040 |
Why?
| | Etoposide | 1 | 2017 | 71 | 0.040 |
Why?
| | Erythroid Cells | 1 | 2017 | 5 | 0.040 |
Why?
| | Genes, Dominant | 1 | 2017 | 19 | 0.040 |
Why?
| | Erythropoiesis | 1 | 2017 | 16 | 0.040 |
Why?
| | Genes, X-Linked | 1 | 2017 | 7 | 0.040 |
Why?
| | Models, Genetic | 1 | 2017 | 174 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1996 | 95 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 467 | 0.030 |
Why?
| | Prevalence | 1 | 2018 | 970 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 374 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 118 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 17 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2017 | 1589 | 0.030 |
Why?
| | Models, Statistical | 1 | 2014 | 226 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 181 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2013 | 111 | 0.030 |
Why?
| | Genotype | 1 | 2013 | 539 | 0.020 |
Why?
| | Thalidomide | 1 | 2013 | 374 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 618 | 0.020 |
Why?
| | Retroviridae | 1 | 2008 | 5 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2009 | 450 | 0.020 |
Why?
| | Anaerobiosis | 1 | 2008 | 18 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2008 | 45 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 106 | 0.020 |
Why?
| | Ankyrin Repeat | 1 | 2007 | 3 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 71 | 0.020 |
Why?
| | Survival Rate | 1 | 2009 | 915 | 0.020 |
Why?
| | Signal Transduction | 1 | 2014 | 1625 | 0.020 |
Why?
| | Fibroblasts | 1 | 2008 | 354 | 0.020 |
Why?
| | Absorption | 1 | 2005 | 21 | 0.020 |
Why?
| | Oxygen | 1 | 2008 | 321 | 0.020 |
Why?
| | Administration, Topical | 1 | 2005 | 57 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 112 | 0.020 |
Why?
| | Skin Diseases | 1 | 2005 | 115 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 509 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2007 | 830 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|